Breast cancer is the most prevalent form of cancer that affects women worldwide,
posing a significant burden on public health. While advancements in early detection and improved treatments have led
to a remarkable 90% five-year survival rate and an 83% ten-year survival rate, this
has also resulted in more prophylactic mastectomies being performed. Despite
advancements in breast-conserving techniques, immunotherapy, and hormone
therapy, many women still undergo mastectomies as part of their cancer treatment.
In all cases, this results in scarring, and additional side effects from treatment
modalities may arise. The loss of a breast can profoundly impact health-related quality of life (HRQoL). Although HRQoL has improved greatly during the recent years, systematic and local
therapy having side effects is not uncommon, and this needs more attention.
